Asia-Pacific Healthcare Contract Development and Manufacturing Organization (CDMO) Market Growth, Size, Share, Industry Report and Forecast 2020-2026

The Asia-Pacific healthcare CDMO market is estimated to grow significantly during the forecast period. The market is mainly driven due to the growing demand for generics drugs in the region. Cost benefits owing to low labor costs and capital expenditures are the key reasons for outsourcing to the Asia-Pacific region. India has been established as a prominent player, specifically in the manufacturing of solid dosage forms for the large-scale production of generics for the global markets. Further, generic companies in India such as Cipla Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., and Cadila Healthcare Ltd. have developed into major global generics players and further contribute to the healthcare CDMO market growth.

To Request a Sample of our Report on Asia-Pacific Healthcare Contract Development and Manufacturing Organization (CDMO) Market: https://www.omrglobal.com/request-sample/asia-pacific-healthcare-cdmo-market

The Asia-Pacific market for healthcare CDMO is segregated on the basis of services and region. Based on services, the market is further classified into contract development and contract manufacturing. The contract manufacturing services segment is projected to have a significant share in the Asia-Pacific healthcare CDMO market owing to the significant adoption of outsourcing services by pharmaceutical companies across the globe. The contract development services are further classified into clinical, preclinical, and laboratory services. The clinical segment is projected to have significant growth in the market owing to increasing clinical research.

Moreover, the contract manufacturing services segment is further classified into API, finished dosage formulations, and medical devices. The API contract manufacturing services segment is significantly contributing to the growth of the market during the forecast period. Based on geography, the Asia-Pacific healthcare CDMO market is further segregated into China, India, Japan, and the Rest of Asia-Pacific. China is projected to have a considerable share in the Asia-Pacific healthcare CDMO market owing to significant investment in drug discovery and development in the country.

(Get 15% Discount on Buying this Report)
A full Report of Asia-Pacific Healthcare Contract Development and Manufacturing Organization (CDMO) Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-healthcare-cdmo-market

Asia-Pacific Healthcare CDMO Market Segmentation

By Services
• Contract Development
• Clinical
• Preclinical
• Laboratory Services
• Contract Manufacturing
• Active Pharmaceutical Ingredients (API)
• Finish Dosage Formulations
• Medical Devices
Regional Analysis
• China
• India
• Japan
• Rest of Asia-Pacific

Company Profiles
• AbbVie Inc.
• Almac Group Ltd.
• Baxter International, Inc.
• B. Braun Melsungen AG
• Boehringer Ingelheim International GmbH
• Catalent Inc.
• Covance Inc.
• Lonza Group Ltd.
• Pfizer Inc.
• Thermo Fisher Scientific Inc.

Reasons for Buying from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-healthcare-cdmo-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.